Deepak Jain | Chief Operating Officer
inRegen

Deepak Jain, Chief Operating Officer, inRegen

Dr. Jain is the Chief Operating Officer for Twin City Bio/inRegen, a cell-based therapy company and has over 39 years of experience in biotechnology, tissue engineering, cell therapy and regenerative medicine bioprocess research & development and GMP manufacturing. Twin City Bio/inRegen is developing a revolutionary cell therapy that harnesses the body’s intrinsic ability to repair and restore damaged kidney tissues to native-like organs and tissues. Prior to Twin City Bio, Dr. Jain co-founded RegenMedTX in 2015 as Chief Operating Officer which acquired the assets of Tengion Inc where Dr Jain was the Senior Vice President of Bioprocess R&D and Technical Operations. Prior to Tengion, Dr. Jain was the Executive Director of Process Development and Manufacturing Technical Support at Advanced Tissue Sciences responsible for development of human-based tissue engineered products for therapeutic applications in the skin, cartilage and cardiovascular areas. Dr. Jain has held several positions of increasing technical and management responsibility at Merck and Johnson & Johnson, leading the development of biotechnology products with a focus on recombinant proteins. Dr. Jain was instrumental in the development and manufacturing support of J&J’s multi-billion-dollar product for the treatment of anemia. At Baxter Corporation Dr Jain was responsible for establishing a commercial manufacturing facility overseas for a marketed recombinant protein. Dr. Jain is accomplished at directing product development from research to the clinic, process scale-up, technology transfers, GMP facility design, process validation and manufacturing of biotechnology-derived recombinant proteins and tissue engineered cell therapy and regenerative medicine products. He is highly experienced in regulatory CMC submissions for biologics, devices and combination products. Dr. Jain served as the Chairman of Cell Therapy Ad hoc Advisory Panel for United States Pharmacopoeia and as a member of USP’s Biologics & Biotechnology Expert Committee. Dr. Jain has also served as Chairman of the American Society for Testing and Materials Task Group on Preservation of Cells and Tissue Engineered Medical Product’s with Cells. Dr. Jain has over 70 publications, presentations and abstracts, two book chapters and many patents in the field biologics, tissue engineering, cell therapy and regenerative medicine. Dr. Jain received a PhD from the Indian Institute of Technology, Delhi in Biochemical Engineering.

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 14:40

New clinical data: Effects of an autologous cell therapy in patients with advanced chronic kidney disease associated with diabetes mellitus

last published: 04/Jun/20 08:25 GMT

back to speakers